{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T03:16:10Z","timestamp":1782011770499,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s41669-024-00534-2","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T19:02:41Z","timestamp":1730919761000},"page":"125-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line Treatment"],"prefix":"10.1007","volume":"9","author":[{"given":"Yan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2160-0942","authenticated-orcid":false,"given":"Ella X.","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasvi","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Eiffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Beauchamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rosenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"issue":"3","key":"534_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"534_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"534_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nrurol.2010.46","volume":"7","author":"WH Chow","year":"2010","unstructured":"Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245\u201357.","journal-title":"Nat Rev Urol"},{"key":"534_CR4","unstructured":"National Cancer Institute. Cancer Stat Facts: Kidney and Renal Pelvis Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html. Accessed 1 Dec 2023."},{"key":"534_CR5","doi-asserted-by":"publisher","first-page":"175883592110347","DOI":"10.1177\/17588359211034708","volume":"13","author":"DJ George","year":"2021","unstructured":"George DJ, Lee C-H, Heng D. New approaches to first-line treatment of advanced renal cell carcinoma. Ther Adv Med Oncol. 2021;13:17588359211034708.","journal-title":"Ther Adv Med Oncol."},{"key":"534_CR6","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae)\u2014Kidney Cancer Version 1.2024 2023."},{"key":"534_CR7","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3389\/fphar.2019.01173","volume":"10","author":"L Gao","year":"2019","unstructured":"Gao L, Yang X, Yi C, Zhu H. Adverse events of concurrent immune checkpoint inhibitors and antiangiogenic agents: a systematic review. Front Pharmacol. 2019;10:1173.","journal-title":"Front Pharmacol"},{"issue":"4","key":"534_CR8","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3390\/cancers15041048","volume":"15","author":"E Granet-Vaissiere","year":"2023","unstructured":"Granet-Vaissiere E, Lefort F, Domblides C, et al. Combinations of anti-angiogenic agents and immune checkpoint inhibitors in renal cell carcinoma: best option? Cancers (Basel). 2023;15(4):1048.","journal-title":"Cancers (Basel)."},{"issue":"11","key":"534_CR9","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3111\/13696998.2014.945645","volume":"17","author":"R Borker","year":"2014","unstructured":"Borker R. Costs associated with adverse events in patients with metastatic renal cell carcinoma. J Med Econ. 2014;17(11):792\u20137.","journal-title":"J Med Econ"},{"issue":"12","key":"534_CR10","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/j.clinthera.2013.10.010","volume":"35","author":"M Hagiwara","year":"2013","unstructured":"Hagiwara M, Borker R, Oster G. Economic burden of adverse events in patients with metastatic renal cell carcinoma. Clin Ther. 2013;35(12):1955-63.e2.","journal-title":"Clin Ther"},{"issue":"1","key":"534_CR11","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/oncolo\/oyac186","volume":"28","author":"B McGregor","year":"2023","unstructured":"McGregor B, Geynisman DM, Burotto M, et al. Grade 3\/4 adverse event costs of immuno-oncology combination therapies for previously untreated advanced renal cell carcinoma. Oncologist. 2023;28(1):72\u20139.","journal-title":"Oncologist"},{"key":"534_CR12","unstructured":"U.S. Food and Drug Administration. OPDIVO - Nivolumab injection. https:\/\/www.accessdata.fda.gov\/spl\/data\/029e0283-4b1b-4ab2-9782-9f2ce2713dd1\/029e0283-4b1b-4ab2-9782-9f2ce2713dd1.xml."},{"key":"534_CR13","unstructured":"U.S. Food and Drug Administration. KEYTRUDA. https:\/\/www.accessdata.fda.gov\/spl\/data\/18646d26-9d9a-4c6b-8926-8402fab7243b\/18646d26-9d9a-4c6b-8926-8402fab7243b.xml."},{"issue":"33","key":"534_CR14","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.2217\/fon-2019-0434","volume":"15","author":"P Grivas","year":"2019","unstructured":"Grivas P, DerSarkissian M, Shenolikar R, Lalibert\u00e9 F, Doleh Y, Duh MS. Healthcare resource utilization and costs of adverse events among patients with metastatic urothelial cancer in USA. Future Oncol. 2019;15(33):3809\u201318.","journal-title":"Future Oncol"},{"issue":"4","key":"534_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196007","volume":"13","author":"W Wong","year":"2018","unstructured":"Wong W, Yim YM, Kim A, et al. Assessment of costs associated with adverse events in patients with cancer. PLoS ONE. 2018;13(4): e0196007.","journal-title":"PLoS ONE"},{"key":"534_CR16","unstructured":"US Bureau of Labor Statistics. Consumer Price Index. https:\/\/www.bls.gov\/cpi\/factsheets\/medical-care.htm. Accessed 1 Dec 2023."},{"issue":"3","key":"534_CR17","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/intqhc\/mzr010","volume":"23","author":"D Gregori","year":"2011","unstructured":"Gregori D, Petrinco M, Bo S, Desideri A, Merletti F, Pagano E. Regression models for analyzing costs and their determinants in health care: an introductory review. Int J Quality Health Care. 2011;23(3):331\u201341.","journal-title":"Int J Quality Health Care."},{"issue":"24","key":"534_CR18","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","volume":"34","author":"LE Schnipper","year":"2016","unstructured":"Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34(24):2925\u201334.","journal-title":"J Clin Oncol"},{"issue":"19","key":"534_CR19","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814\u201323.","journal-title":"N Engl J Med"},{"issue":"14","key":"534_CR20","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer R, Alekseev B, Rha S-Y, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289\u2013300.","journal-title":"N Engl J Med"},{"issue":"2","key":"534_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115\u201324.","journal-title":"N Engl J Med"},{"key":"534_CR22","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022.","DOI":"10.1016\/S1470-2045(22)00290-X"},{"issue":"14","key":"534_CR23","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u201390.","journal-title":"N Engl J Med"},{"issue":"49","key":"534_CR24","first-page":"834","volume":"113","author":"D Berliner","year":"2016","unstructured":"Berliner D, Schneider N, Welte T, Bauersachs J. The differential diagnosis of dyspnea. Dtsch Arztebl Int. 2016;113(49):834\u201345.","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"534_CR25","first-page":"711","volume":"57","author":"WC Morgan","year":"1998","unstructured":"Morgan WC, Hodge HL. Diagnostic evaluation of dyspnea. Am Fam Physician. 1998;57(4):711\u20136.","journal-title":"Am Fam Physician"},{"key":"534_CR26","doi-asserted-by":"crossref","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6).","DOI":"10.1136\/jitc-2021-002435"},{"key":"534_CR27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.2147\/CEOR.S138963","volume":"9","author":"C Chouaid","year":"2017","unstructured":"Chouaid C, Loirat D, Clay E, et al. Cost analysis of adverse events associated with non-small cell lung cancer management in France. Clinicoecon Outcomes Res. 2017;9:443\u20139.","journal-title":"Clinicoecon Outcomes Res."},{"issue":"6","key":"534_CR28","first-page":"729","volume":"26","author":"NM Engel-Nitz","year":"2020","unstructured":"Engel-Nitz NM, Johnson MP, Bunner SH, Ryan KJ. Real-world costs of adverse events in first-line treatment of metastatic non-small cell lung cancer. J Manag Care Spec Pharm. 2020;26(6):729\u201340.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"534_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2215\/CJN.03530412","volume":"8","author":"AK Salahudeen","year":"2013","unstructured":"Salahudeen AK, Doshi SM, Pawar T, Nowshad G, Lahoti A, Shah P. Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin J Am Soc Nephrol. 2013;8(3):347\u201354.","journal-title":"Clin J Am Soc Nephrol"},{"key":"534_CR30","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.36740\/WLek201911201","volume":"72","author":"M Dylewska","year":"2019","unstructured":"Dylewska M, Chomicka I, Malyszko J. Hypertension in patients with acute kidney injury. Wiad Lek. 2019;72:2199\u2013201.","journal-title":"Wiad Lek"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00534-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-024-00534-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00534-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T13:04:53Z","timestamp":1736427893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-024-00534-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1007\/s41669-024-00534-2","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"2 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Bristol Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yan Chen, Ella X. Du, Manasvi Sundar, and Keith A. Betts are employees of Analysis Group, Inc., which provided paid consulting services to Bristol Myers Squibb, the study sponsor. Lisa Rosenblatt is an employee of Bristol Myers Squibb, the study sponsor, who may own stock\/stock options. Xin Yin was a consultant for Bristol Myers Squibb, the study sponsor, at the time of the study. Samantha Eiffert was a doctoral fellow at Bristol Myers Squibb, the study sponsor, at the time of the study. Karen Beauchamp and Andrew Delgado were employees of Bristol Myers Squibb, the study sponsor, at the time of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All data analyzed in this study were derived from the privately held Merative MarketScan Commercial Database and are not publicly available.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"This study used deidentified data and was exempt from institutional review board (IRB) review. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Codes are proprietary assets of Analysis Group and thus cannot be made available.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization: Keith A. Betts, Ella X. Du, Xin Yin, Karen Beauchamp, Andrew Delgado, Lisa Rosenblatt; Methodology: Keith A. Betts, Yan Chen, Ella X. Du, Xin Yin, Samantha Eiffert, Karen Beauchamp, Andrew Delgado, Lisa Rosenblatt; Formal analysis and investigation: Keith A. Betts, Yan Chen, Ella X. Du, Manasvi Sundar, Xin Yin, Samantha Eiffert, Karen Beauchamp, Andrew Delgado, Lisa Rosenblatt; Writing\u2014original draft preparation: Keith A. Betts, Yan Chen, Ella X. Du, Manasvi Sundar; Writing\u2014review and editing: Keith A. Betts, Yan Chen, Ella X. Du, Manasvi Sundar, Xin Yin, Samantha Eiffert, Karen Beauchamp, Andrew Delgado, Lisa Rosenblatt; Funding acquisition: Xin Yin, Lisa Rosenblatt; Resources: Lisa Rosenblatt; Supervision: Xin Yin. All authors have read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}